Skip to main content
SpringerLink
Log in

Dermatological adverse events with taxane chemotherapy

  • Review
  • Published:
European Journal of Dermatology Aims and scope

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, prostate, gastric, head and neck, and ovarian cancers, as well as in the adjuvant setting for operable node-positive breast cancers. Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent one of the major AEs associated with these agents. With an increase in the occurrence of cutaneous AEs during treatment with novel targeted and immunological therapies when used in combination with taxanes, a thorough understanding of reactions attributable to this class is imperative. Moreover, identification and management of dermatological AEs is critical for maintaining the quality of life in cancer patients and for minimizing dose modifications of their antineoplastic regimen. This analysis represents a systematic review of the dermatological conditions reported with the use of these drugs, complemented by experience at comprehensive cancer centres. The conditions reported herein include skin, hair, and nail toxicities. Lastly, we describe the dermatological data available for the new, recently FDA-and EMA- approved, solvent-free nab-paclitaxel.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332: 1004–14.

    Article  CAS  PubMed  Google Scholar 

  2. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643–55.

    CAS  PubMed  Google Scholar 

  3. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994; 344: 1267–72.

    Article  CAS  PubMed  Google Scholar 

  4. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–703.

    Article  CAS  Google Scholar 

  5. Markman M. Managing taxane toxicities. Support Care Cancer 2003; 11: 144–7.

    PubMed  Google Scholar 

  6. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542–51.

    Article  CAS  PubMed  Google Scholar 

  8. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27: 3611–9.

    Article  CAS  PubMed  Google Scholar 

  9. Trudeau ME. Docetaxel (Taxotere): an overview of first-line monotherapy. Semin Oncol 1995; 22: 17–21.

    CAS  PubMed  Google Scholar 

  10. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinumbased therapy REVEL: a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384: 665–73.

    Article  CAS  PubMed  Google Scholar 

  11. Zimmerman GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995; 131: 202–6.

    Article  CAS  PubMed  Google Scholar 

  12. Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 2006; 33: 86–97.

    Article  CAS  PubMed  Google Scholar 

  13. Poi MJ, Berger M, Lustberg M, et al. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer 2013; 21: 2679–86.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Poikonen P, Sjostrom J, Klaar S, et al. Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel. Acta Oncol 2004; 43: 190–5.

    Article  CAS  PubMed  Google Scholar 

  15. Susnjar S, Bosnjak SM, Radulovic S. Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. Support Care Cancer 2008; 16: 1415–8.

    Article  PubMed  Google Scholar 

  16. Caiado J, Picard M. Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators. Curr Allergy Asthma Rep 2014; 14: 451.

    Article  PubMed  CAS  Google Scholar 

  17. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009; 102: 179–87.

    Article  PubMed  Google Scholar 

  18. Castells M, Sancho-Serra MC, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother 2012; 61: 1575–84.

    Article  CAS  PubMed  Google Scholar 

  19. Piovano E, Pivetta E, Modaffari P, et al. A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms. Gynecol Obstet Invest 2012; 74: 21–7.

    Article  CAS  PubMed  Google Scholar 

  20. Sanchez-Munoz A, Jimenez B, Garcia-Tapiador A, et al. Crosssensitivity between taxanes in patients with breast cancer. Clin Transl Oncol 2011; 13: 904–6.

    Article  CAS  PubMed  Google Scholar 

  21. Kimura K, Tanaka S, Iwamoto M, et al. Safety of nanoparticle albumin-bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: four case reports. Oncol Lett 2013; 6: 881–4.

    PubMed  PubMed Central  Google Scholar 

  22. Raisch DW, Campbell W, Garg V, et al. Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opin Drug Saf 2011; 10: 521–8.

    Article  CAS  PubMed  Google Scholar 

  23. Syrigou E, Dannos I, Kotteas E, et al. Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 2011; 156: 320–4.

    Article  CAS  PubMed  Google Scholar 

  24. O’Cathail SM, Shaboodien R, Mahmoud S, et al. Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies. Int J Gynecol Cancer 2013; 23: 1318–25.

    Article  PubMed  Google Scholar 

  25. Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel Taxotere. Ann Oncol 1993; 4: 610–1.

    CAS  PubMed  Google Scholar 

  26. de Leon MC, Bolla S, Greene B, et al. Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel. Gynecol Oncol Case Rep 2013; 5: 70–1.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013; 68: 853–61.

    Article  CAS  PubMed  Google Scholar 

  28. Barbee MS, Owonikoko TK, Harvey RD. Taxanes: vesicants, irritants, or just irritating? Ther Adv Med Oncol 2014; 6: 16–20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Stanford BL, Hardwicke F. A review of clinical experience with paclitaxel extravasations. Support Care Cancer 2003; 11: 270–7.

    PubMed  Google Scholar 

  30. Link CJ Jr., Sarosy GA, Kohn EC, et al. Cutaneous manifestations of Taxol therapy. Invest New Drugs 1995; 13: 261–3.

    Article  CAS  PubMed  Google Scholar 

  31. Ley BD, Millan GG, Perez JS, et al. Docetaxel recall phenomenon at the site of previous drug extravasation. Arch Dermatol 2010; 146: 1190–1.

    Article  PubMed  Google Scholar 

  32. Ascherman JA, Knowles SL, Attkiss K. Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations. Ann Plast Surg 2000; 45: 438–41.

    Article  CAS  PubMed  Google Scholar 

  33. Gallo E, Llamas-Velasco M, Navarro R, et al. Eccrine squamous syringometaplasia secondary to cutaneous extravasation of docetaxel: report of three cases. J Cutan Pathol 2013; 40: 326–9.

    PubMed  Google Scholar 

  34. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 2008; 58: 545–70.

    Article  PubMed  Google Scholar 

  35. Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs 2011; 27: 82–90.

    Article  PubMed  Google Scholar 

  36. Perez Fidalgo JA, Garcia FL, Cervantes A. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012; 23(7): vii167–73.

    PubMed  Google Scholar 

  37. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40: 367–98.

    Article  CAS  PubMed  Google Scholar 

  38. Gonzalez T. Chemotherapy extravasations: prevention, identification, management, and documentation. Clin J Oncol Nurs 2013; 17: 61–6.

    Article  PubMed  Google Scholar 

  39. Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer READY: a randomised, double-blind phase 3 trial. Lancet Oncol 2013; 14: 1307–16.

    Article  CAS  PubMed  Google Scholar 

  40. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59: 524–9.

    Article  PubMed  Google Scholar 

  41. Childress J, Lokich J. Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol 2003; 26: 435–6.

    Article  PubMed  Google Scholar 

  42. Spicknall KE, Mutasim DF. Localized toxic erythema of chemotherapy during treatment with paclitaxel. Int J Dermatol 2014; 53: e3–5.

    Article  CAS  Google Scholar 

  43. Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs 2014; 25: 225–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Moisidis C, Mobus V. Erythema multiforme major following docetaxel. Arch Gynecol Obstet 2005; 271: 267–9.

    Article  CAS  PubMed  Google Scholar 

  45. Dourakis SP, Sevastianos VA, Alexopoulou A, et al. Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy. J Clin Oncol 2002; 20: 3030–2.

    CAS  PubMed  Google Scholar 

  46. Hiraki A, Aoe K, Murakami T, Maeda T, Eda R, Takeyama H. Stevens-Johnson syndrome induced by paclitaxel in a patient with squamous cell carcinoma of the lung: a case report. Anticancer Res 2004; 24: 1135–7.

    PubMed  Google Scholar 

  47. Sawada Y, Sugita K, Kabashima R, et al. Docetaxel-induced Stevens-Johnson syndrome with regenerating epidermis composed of atypical keratinocytes. J Eur Acad Dermatol Venereol 2009; 23: 1333–5.

    Article  CAS  PubMed  Google Scholar 

  48. Adachi A, Horikawa T. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol 2007; 34: 473–6.

    Article  PubMed  Google Scholar 

  49. Lowe G, Henderson CL, Grau RH, et al. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2011; 164: 465–72.

    CAS  PubMed  Google Scholar 

  50. Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 2004; 31: 818–20.

    PubMed  Google Scholar 

  51. Marchetti MA, Noland MM, Dillon PM, et al. Taxane associated subacute cutaneous lupus erythematosus. Dermatol Online J 2013; 19: 19259.

    CAS  PubMed  Google Scholar 

  52. Wong NY, Parsons LM, Trotter MJ, et al. Drug-induced subacute cutaneous lupus erythematosus associated with docetaxel chemotherapy: a case report. BMC Res Notes 2014; 7: 785.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011; 34: 357–74.

    Article  CAS  PubMed  Google Scholar 

  54. Lamond NW, Younis T, Purdy K, et al. Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy. Curr Oncol 2013; 20: e484–7.

    Article  Google Scholar 

  55. Ferreira O, Baudrier T, Mota A, et al. Docetaxel-induced acral erythema and nail changes distributed to photoexposed areas. Cutan Ocul Toxicol 2010; 29: 296–9.

    Article  CAS  PubMed  Google Scholar 

  56. Tokunaga M, Iga N, Endo Y, et al. Elevated protoporphyrin in patients with skin cancer receiving taxane chemotherapy. Eur J Dermatol 2013; 23: 826–9.

    PubMed  Google Scholar 

  57. Cohen PR. Photodistributed erythema multiforme: paclitaxelrelated, photosensitive conditions in patients with cancer. J Drugs Dermatol 2009; 8: 61–4.

    PubMed  Google Scholar 

  58. Ji YZ, Geng L, Qu HM, et al. Acute generalized exanthematous pustulosis induced by docetaxel. Int J Dermatol 2011; 50: 763–5.

    Article  PubMed  Google Scholar 

  59. Weinberg JM, Egan CL, Tangoren IA, et al. Generalized pustular dermatosis following paclitaxel therapy. Int J Dermatol 1997; 36: 559–60.

    Article  CAS  PubMed  Google Scholar 

  60. Kim SW, Lee UH, Jang SJ, et al. Acute localized exanthematous pustulosis induced by docetaxel. J Am Acad Dermatol 2010; 63: e44–6.

    Article  Google Scholar 

  61. Belda-Iniesta C, Casado E, Corral DLC, Castelo B, Baron MG. Re: Folliculitis associated with weekly paclitaxel treatment. J Natl Cancer Inst 2003; 95: 410.

    Article  PubMed  Google Scholar 

  62. Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist 2010; 15: 1227–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002; 14: 212–6.

    Article  CAS  PubMed  Google Scholar 

  64. Borgia F, Guarneri C, Guarneri F, et al. Radiation recall dermatitis after docetaxel administration: absolute indication to replace the drug? Br J Dermatol 2005; 153: 674–5.

    Article  CAS  PubMed  Google Scholar 

  65. Morkas M, Fleming D, Hahl M. Challenges in oncology. Case 2. Radiation recall associated with docetaxel. J Clin Oncol 2002; 20: 867–9.

    PubMed  Google Scholar 

  66. Mizumoto M, Harada H, Asakura H, et al. Frequency and characteristics of docetaxel-induced radiation recall phenomenon. Int J Radiat Oncol Biol Phys 2006; 66: 1187–91.

    Article  CAS  PubMed  Google Scholar 

  67. Phillips KA, Urch M, Bishop JF. Radiation-recall dermatitis in a patient treated with paclitaxel. J Clin Oncol 1995; 13: 305.

    CAS  PubMed  Google Scholar 

  68. Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 2006; 7: 45–63.

    Article  PubMed  Google Scholar 

  69. Sanborn RE, Sauer DA. Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. Dermatol Clin 2008; 26: 103–19, ix.

    Article  CAS  PubMed  Google Scholar 

  70. Koppel RA, Boh EE. Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 2001; 321: 327–35.

    Article  CAS  PubMed  Google Scholar 

  71. Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin North Am 1986; 70: 187–209.

    Article  CAS  PubMed  Google Scholar 

  72. Droitcourt C, Le Ho H, Adamski H, et al. Docetaxel-induced photo-recall phenomenon. Photodermatol Photoimmunol Photomed 2012; 28: 222–3.

    Article  PubMed  Google Scholar 

  73. Ee HL, Yosipovitch G. Photo recall phenomenon: an adverse reaction to taxanes. Dermatology 2003; 207: 196–8.

    Article  PubMed  Google Scholar 

  74. Kazandjieva J, Gergovska M, Darlenski R, et al. Recall dermatitis after systemic treatment with paclitaxel. Int J Dermatol 2010; 49: 956–9.

    Article  PubMed  Google Scholar 

  75. Corazza M, Minghetti S, Borghi A, et al. Hand-foot syndrome caused by docetaxel with no recurrence after switch to paclitaxel, a different taxane. Int J Dermatol 2014; 53: e180–2.

    Article  CAS  Google Scholar 

  76. Eich D, Scharffetter-Kochanek K, Eich HT, et al. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol 2002; 25: 599–602.

    Article  PubMed  Google Scholar 

  77. Stravodimou A, Voutsadakis IA. Hand and foot syndrome associated with docetaxel treatment. Acta Oncol 2012; 51: 554–6.

    Article  CAS  PubMed  Google Scholar 

  78. Harris CS, Wang D, Carulli A. Docetaxel-associated palmarplantar erythrodysesthesia: a case report and review of the literature. J Oncol Pharm Pract 2014; 20: 73–80.

    Article  PubMed  Google Scholar 

  79. Bardia A, Loprinzi CL, Goetz MP. Hand-foot syndrome after dosedense adjuvant chemotherapy for breast cancer: a case series. J Clin Oncol 2006; 24: e18–9.

    Article  Google Scholar 

  80. Kawaguchi K, Ishiguro H, Morita S, et al. Correlation between docetaxel-induced skin toxicity and the use of steroids and H(2) blockers: a multi-institution survey. Breast Cancer Res Treat 2011; 130: 627–34.

    Article  CAS  PubMed  Google Scholar 

  81. Housholder AL, Adams BB. Chemotherapy-induced acral erythema sparing the palms. J Am Acad Dermatol 2012; 67: e116–7.

    Article  Google Scholar 

  82. de Argila D, Dominguez JD, Iglesias L. Taxol-induced acral erythema. Dermatology 1996; 192: 377–8.

    Article  PubMed  Google Scholar 

  83. Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced handfoot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71: 787–94.

    Article  PubMed  Google Scholar 

  84. Nagore E, Insa A, Sanmartin O. Antineoplastic therapyinduced palmar plantar erythrodysesthesia (“hand-foot”) syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225–34.

    Article  CAS  PubMed  Google Scholar 

  85. Chew L, Chuen VS. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 2009; 15: 29–34.

    Article  CAS  PubMed  Google Scholar 

  86. Sibaud V, Dalenc F, Chevreau C, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 2011; 16: 1469–78.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Scotte F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005; 23: 4424–9.

    Article  PubMed  Google Scholar 

  88. Chen M, Zhang L, Wang Q, et al. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review. PLoS One 2013; 8: e72245.

    Article  CAS  Google Scholar 

  89. Macedo LT, Lima JP, Dos Santos LV, et al. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer 2014; 22: 1585–93.

    PubMed  Google Scholar 

  90. Correia O, Azevedo C, Pinto FE, et al. Nail changes secondary to docetaxel Taxotere. Dermatology 1999; 198: 288–90.

    Article  CAS  PubMed  Google Scholar 

  91. Chu CY, Yang CH, Yang CY, et al. Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 2000; 142: 808–11.

    Article  CAS  PubMed  Google Scholar 

  92. Sibaud V, Fricain JC, Baran R, et al. Pigmentary disorders induced by anticancer agents. Part I: chemotherapy. Ann Dermatol Venereol 2013; 140: 183–96.

    Article  CAS  PubMed  Google Scholar 

  93. Baykal C, Erkek E, Tutar E, et al. Cutaneous fixed drug eruption to paclitaxel; a case report. Eur J Gynaecol Oncol 2000; 21: 190–1.

    CAS  PubMed  Google Scholar 

  94. Ghosh SK, Bandyopadhyay D, Ghoshal L, et al. Docetaxelinduced supravenous serpentine dermatitis. Dermatol Online J 2011; 17: 16.

    PubMed  Google Scholar 

  95. Schrijvers D, Van Den BJ, Vermorken JB. Supravenous discoloration of the skin due to docetaxel treatment. Br J Dermatol 2000; 142: 1069–70.

    Article  CAS  PubMed  Google Scholar 

  96. Aydogan I, Kavak A, Parlak AH, et al. Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel. J Eur Acad Dermatol Venereol 2005; 19: 345–7.

    Article  CAS  PubMed  Google Scholar 

  97. Masson Regnault M, Gadaud N, Boulinguez S, et al. Chemotherapy-related reticulate hyperpigmentation: a case series and review of the literature. Dermatology 2015; 231: 312–8.

    Article  CAS  PubMed  Google Scholar 

  98. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16: 3426–32.

    CAS  PubMed  Google Scholar 

  99. Behar A, Pujade-Lauraine E, Maurel A, et al. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 1997; 43: 653–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Ellis P, Barrett-Lee P, Johnson L, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an openlabel, phase III, randomised controlled trial. Lancet 2009; 373: 1681–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Von Hoff DD. The taxoids: same roots, different drugs. Semin Oncol 1997; 24: S13.

    Google Scholar 

  102. Ohsumi S, Shimozuma K, Ohashi Y, et al. Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The National Surgical Adjuvant Study of Breast Cancer 02. Oncology 2012; 82: 131–8.

    Article  CAS  PubMed  Google Scholar 

  103. Kupfer I, Balguerie X, Courville P, et al. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study. J Am Acad Dermatol 2003; 48: 279–81.

    Article  CAS  PubMed  Google Scholar 

  104. Konishi Y, Sato H, Sato N, et al. Scleroderma-like cutaneous lesions induced by paclitaxel and carboplatin for ovarian carcinoma, not a single course of carboplatin, but re-induced and worsened by previously administrated paclitaxel. J Obstet Gynaecol Res 2010; 36: 693–6.

    Article  PubMed  Google Scholar 

  105. Lauchli S, Trueb RM, Fehr M, et al. Scleroderma-like drug reaction to paclitaxel Taxol. Br J Dermatol 2002; 147: 619–21.

    Article  CAS  PubMed  Google Scholar 

  106. Itoh M, Yanaba K, Kobayashi T, et al. Taxane-induced scleroderma. Br J Dermatol 2007; 156: 363–7.

    Article  CAS  PubMed  Google Scholar 

  107. Battafarano DF, Zimmerman GC, Older SA, et al. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 1995; 76: 110–5.

    Article  CAS  PubMed  Google Scholar 

  108. Farrant PB, Mortimer PS, Gore M. Scleroderma and the taxanes. Is there really a link? Clin Exp Dermatol 2004; 29: 360–2.

    Article  CAS  PubMed  Google Scholar 

  109. Pedersen JV, Jensen S, Krarup-Hansen A, et al. Scleroderma induced by paclitaxel. Acta Oncol 2010; 49: 866–8.

    Article  PubMed  Google Scholar 

  110. Trueb RM. Chemotherapy-induced hair loss. Skin Therapy Lett 2010; 15: 5–7.

    CAS  PubMed  Google Scholar 

  111. Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapyinduced alopecia: case report and review of the literature. J Am Acad Dermatol 2010; 63: 333–6.

    Article  PubMed  Google Scholar 

  112. Trueb RM. Chemotherapy-induced anagen effluvium: diffuse or patterned? Dermatology 2007; 215: 1–2.

    Article  PubMed  Google Scholar 

  113. Paus R, Haslam IS, Sharov AA, et al. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol 2013; 14: e50–9.

    Article  CAS  Google Scholar 

  114. Palamaras I, Misciali C, Vincenzi C, et al. Permanent chemotherapy-induced alopecia: a review. J Am Acad Dermatol 2011; 64: 604–6.

    Article  PubMed  Google Scholar 

  115. Miteva M, Misciali C, Fanti PA, et al. Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases. Am J Dermatopathol 2011; 33: 345–50.

    Article  PubMed  Google Scholar 

  116. Kluger N, Jacot W, Frouin E, et al. Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 2012; 23: 2879–84.

    Article  CAS  PubMed  Google Scholar 

  117. Bourgeois H, Denis F, Kerbrat P, et al. Long-term persistent alopecia and suboptimal hair regrowth after adjuvant chemotherapy for breast cancer: alert for an emerging side effect: ALOPERS Observatory. Cancer Res 2009; 69: s703–4.

    Article  Google Scholar 

  118. Prevezas C, Matard B, Pinquier L, et al. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 2009; 160: 883–5.

    Article  CAS  PubMed  Google Scholar 

  119. Tosti A, Palamaras I, Miteva M, et al. Docetaxel and permanent alopecia. J Am Acad Dermatol 2013; 68: e151.

    Article  Google Scholar 

  120. Saggar V, Wu S, Dickler MN, et al. Alopecia with endocrine therapies in patients with cancer. Oncologist 2013; 18: 1126–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Mols F, van den Hurk CJ, Vingerhoets AJ, et al. Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support Care Cancer 2009; 17: 181–9.

    Article  PubMed  Google Scholar 

  122. van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients-results of the Dutch Scalp Cooling Registry. Acta Oncol 2012; 51: 497–504.

    Article  PubMed  CAS  Google Scholar 

  123. van den Hurk CJ, Breed WP, Nortier JW. Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 2012; 20: 3255–60.

    Article  PubMed  Google Scholar 

  124. Betticher DC, Delmore G, Breitenstein U, et al. Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Support Care Cancer 2013; 21: 2565–73.

    Article  PubMed  Google Scholar 

  125. Komen MM, Smorenburg CH, van den Hurk CJ, et al. Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist 2013; 18: 885–91.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Yeager CE, Olsen EA. Treatment of chemotherapy-induced alopecia. Dermatol Ther 2011; 24: 432–42.

    Article  PubMed  Google Scholar 

  127. Lotfi-Jam K, Carey M, Jefford M, et al. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 2008; 26: 5618–29.

    Article  PubMed  Google Scholar 

  128. Masidonski P, Mahon SM. Permanent alopecia in women being treated for breast cancer. Clin J Oncol Nurs 2009; 13: 13–4.

    PubMed  Google Scholar 

  129. Ahluwalia GS. Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss. J Investig Dermatol Symp Proc 2013; 16: S73–6.

    Article  CAS  PubMed  Google Scholar 

  130. Minisini AM, Tosti A, Sobrero AF, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 2003; 14: 333–7.

    Article  CAS  PubMed  Google Scholar 

  131. Matsumoto K, Hino C, Fukada K, et al. Prospective study of ice gel pack as less expensive alternative for prevention of skin and nail toxicity in patients with breast cancer receiving docetaxel. Cancer Res 2009; 69, Abstract 1114.

    Google Scholar 

  132. Can G, Aydiner A, Cavdar I. Taxane-induced nail changes: predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. Eur J Oncol Nurs 2012; 16: 270–5.

    Article  PubMed  Google Scholar 

  133. Winther D, Saunte DM, Knap M, et al. Nail changes due to docetaxel-a neglected side effect and nuisance for the patient. Support Care Cancer 2007; 15: 1191–7.

    Article  PubMed  Google Scholar 

  134. Capriotti K, Capriotti JA, Lessin S, et al. The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. Br J Dermatol 2015; 173: 842–5.

    Article  CAS  PubMed  Google Scholar 

  135. Hussain S, Anderson DN, Salvatti ME, et al. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 2000; 88: 2367–71.

    Article  CAS  PubMed  Google Scholar 

  136. Gilbar P, Hain A, Peereboom VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract 2009; 15: 143–55.

    Article  CAS  PubMed  Google Scholar 

  137. Sibaud V, Robert C, Mateus C, et al. Nail toxicities induced by systemic anticancer agents. Lancet Oncol 2015; 16: e181–9.

    Article  CAS  Google Scholar 

  138. Mackay-Wiggan J, Nair KG, Halasz CL. Onycholysis associated with paclitaxel. Cutis 2003; 71: 229–32.

    PubMed  Google Scholar 

  139. Mourad YA, Matta-Muallem M, Shamseddine A. Nail toxicity related to taxanes. Dermatol Online J 2003; 9: 15.

    PubMed  Google Scholar 

  140. Obermair A, Binder M, Barrada M, et al. Onycholysis in patients treated with docetaxel. Ann Oncol 1998; 9: 230–1.

    Article  CAS  PubMed  Google Scholar 

  141. Pavithran K, Doval DC. Nail changes due to docetaxel. Br J Dermatol 2002; 146: 709–10.

    Article  CAS  PubMed  Google Scholar 

  142. Scotte F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 2008; 112: 1625–31.

    Article  PubMed  Google Scholar 

  143. Ghetti E, Piraccini BM, Tosti A. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). J Eur Acad Dermatol Venereol 2003; 17: 459–60.

    Article  CAS  PubMed  Google Scholar 

  144. Spazzapan S, Crivellari D, Lombardi D, et al. Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading? J Clin Oncol 2002; 20: 4404–5.

    Article  PubMed  Google Scholar 

  145. Almagro M, Pozo JD, Garcia J, et al. Nail alterations secondary to pactitaxel therapy. Eur J Dermatol 2000; 10: 146–7.

    CAS  PubMed  Google Scholar 

  146. Wasner G, Hilpert F, Baron R, et al. Clinical picture: nail changes secondary to docetaxel. Lancet 2001; 357: 910.

    Article  CAS  PubMed  Google Scholar 

  147. Speck RM, DeMichele A, Farrar JT, et al. Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies. Support Care Cancer 2013; 21: 549–55.

    Article  PubMed  Google Scholar 

  148. Morrow PK, Mattair DN, Hortobagyi GN. Hot flashes: a review of pathophysiology and treatment modalities. Oncologist 2011; 16: 1658–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Makdsi F, Deversa R. Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report. Cases J 2009; 2: 6946.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Fabbrocini G, Cameli N, Romano MC, et al. Chemotherapy and skin reactions. J Exp Clin Cancer Res 2012; 31: 50.

    Article  PubMed  PubMed Central  Google Scholar 

  151. Ehrlich A, Booher S, Becerra Y, et al. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol 2004; 50: 533–40.

    Article  PubMed  Google Scholar 

  152. Halverstam CP, Lebwohl M. Nonstandard and off-label therapies for psoriasis. Clin Dermatol 2008; 26: 546–53.

    Article  PubMed  Google Scholar 

  153. Kerob D, Le Maignan C, Vignon-Pennamen MD, et al. Docetaxel-induced psoriasis. Ann Dermatol Venereol 2010; 137: 738–40.

    Article  CAS  PubMed  Google Scholar 

  154. Cecco S, Aliberti M, Baldo P, et al. Safety and efficacy evaluation of albumin-bound paclitaxel. Expert Opin Drug Saf 2014; 13: 511–20.

    Article  CAS  PubMed  Google Scholar 

  155. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30: 2055–62.

    Article  CAS  PubMed  Google Scholar 

  156. Ko YJ, Canil CM, Mukherjee SD, et al. Nanoparticle albuminbound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 2013; 14: 769–76.

    Article  CAS  PubMed  Google Scholar 

  157. Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther 2011; 4: 123–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Tang LC, Wang BY, Sun S, et al. Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients. BMC Cancer 2013; 13: 232.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794–803.

    Article  CAS  PubMed  Google Scholar 

  160. Takashima S, Kiyoto S, Takahashi M, et al. Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer. Oncol Lett 2015; 9: 1822–6.

    PubMed  PubMed Central  Google Scholar 

  161. Beutler BD, Cohen PR. Nab-paclitxel-associated photosensitivity: report in a woman with non-small lung cancer and review of taxanerelated photodermatoses. Dermatol Pract Concept 2015; 5: 121–4.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Oncodermatology and Clinical Research, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France

    Vincent Sibaud

  2. Department of Dermatology, Dana–Farber/ Brigham and Women’s Cancer Center/ Harvard Medical School, Boston, MA, USA

    Nicole R. Lebœuf

  3. Department of Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France

    Henri Roche, Laurence Gladieff, Marion Deslandres, Marion Montastruc, Audrey Eche & Florence Dalenc

  4. Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Viswanath R. Belum & Mario E. Lacouture

  5. Department of Oral Medicine, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France

    Emmanuelle Vigarios

Authors
  1. Vincent Sibaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicole R. Lebœuf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henri Roche
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Viswanath R. Belum
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laurence Gladieff
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marion Deslandres
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marion Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Audrey Eche
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Emmanuelle Vigarios
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Florence Dalenc
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mario E. Lacouture
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincent Sibaud.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sibaud, V., Lebœuf, N.R., Roche, H. et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 26, 427–443 (2016). https://doi.org/10.1684/ejd.2016.2833

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2016.2833

Key words

Search

Navigation